Arvinas (ARVN) Total Current Liabilities (2017 - 2026)
Arvinas (ARVN) recorded quarterly Total Current Liabilities of $115.9 million in Q1 2026, down 18.67% quarter-over-quarter from $142.5 million in Q4 2025, and down 45.84% on a YoY basis from $214.0 million in Q1 2025.
Arvinas (ARVN) Total Current Liabilities (2017 - 2026) Analysis & Trends
Arvinas' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $115.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 45.84% year-over-year to $115.9 million; the TTM figure through Mar 2026 stood at $115.9 million (down 45.84% YoY), while the FY2025 annual figure was $142.5 million, down 37.99% from the prior year.
- Total Current Liabilities was $115.9 million for Q1 2026 at Arvinas, down from $142.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $347.2 million in Q2 2024 to a low of $115.9 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $238.2 million across 5 years, with a median of $240.8 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 489.52% in 2022, then tumbled 54.55% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $295.1 million in 2022, then retreated by 12.88% to $257.1 million in 2023, then dropped by 10.62% to $229.8 million in 2024, then plunged by 37.99% to $142.5 million in 2025, then fell by 18.67% to $115.9 million in 2026.
- The last three Total Current Liabilities figures came in at $115.9 million (Q1 2026), $142.5 million (Q4 2025), and $144.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 115.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.90 Mn |
| Dec 31, 2025 | 142.50 Mn |
| Sep 30, 2025 | 144.90 Mn |
| Jun 30, 2025 | 157.80 Mn |
| Mar 31, 2025 | 214.00 Mn |
| Dec 31, 2024 | 229.80 Mn |
| Sep 30, 2024 | 275.90 Mn |
| Jun 30, 2024 | 347.20 Mn |
| Mar 31, 2024 | 240.80 Mn |
| Dec 31, 2023 | 257.10 Mn |
| Sep 30, 2023 | 317.30 Mn |
| Jun 30, 2023 | 306.90 Mn |
| Mar 31, 2023 | 282.90 Mn |
| Dec 31, 2022 | 295.10 Mn |
| Sep 30, 2022 | 244.60 Mn |
| Jun 30, 2022 | 238.20 Mn |
| Mar 31, 2022 | 238.00 Mn |
| Dec 31, 2021 | 261.70 Mn |
| Sep 30, 2021 | 182.51 Mn |
| Jun 30, 2021 | 41.82 Mn |